This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
CNCE 株式概要
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases.
Concert Pharmaceuticals, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$8.37 |
| 52週高値 | US$8.55 |
| 52週安値 | US$2.66 |
| ベータ | 0.52 |
| 11ヶ月の変化 | 0% |
| 3ヶ月変化 | 92.86% |
| 1年変化 | 203.26% |
| 33年間の変化 | -9.22% |
| 5年間の変化 | -64.31% |
| IPOからの変化 | -40.97% |
最新ニュース
Recent updates
Is Concert Pharmaceuticals (NASDAQ:CNCE) In A Good Position To Invest In Growth?
Jan 22
CinCor Pharma hits 52-week high on data for antihypertensive agent
Aug 08Concert Pharmaceuticals: A Balanced Risk/Reward
Jun 15We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate
Jun 04Concert Pharmaceuticals: A Speculative Buy For Their Alopecia Areata Drug
Jun 03Concert Pharmaceuticals (NASDAQ:CNCE) Is In A Good Position To Deliver On Growth Plans
Jan 11Here's Why We're Watching Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation
Aug 27We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate
May 25Concert Pharma EPS beats by $0.02
May 04Concert Pharmaceuticals' (NASDAQ:CNCE) Stock Price Has Reduced 70% In The Past Three Years
Feb 27Concert Pharma fails in mid-stage study for CTP-692 Schizophrenia
Feb 01Here's Why We're Not Too Worried About Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation
Jan 23How Much Of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Do Insiders Own?
Dec 19
A Look At Concert Pharmaceuticals' (NASDAQ:CNCE) Share Price Returns
Nov 23Concert Pharma EPS beats by $0.15
Nov 05Concert Pharma launches late-stage study of CTP-543 in hair loss disorder
Nov 03株主還元
| CNCE | US Biotechs | US 市場 | |
|---|---|---|---|
| 7D | -0.1% | -1.6% | -0.06% |
| 1Y | 203.3% | 10.4% | 20.5% |
業界別リターン: CNCE exceeded the US Biotechs industry which returned 8.9% over the past year.
リターン対市場: CNCE exceeded the US Market which returned -5.5% over the past year.
価格変動
| CNCE volatility | |
|---|---|
| CNCE Average Weekly Movement | 10.4% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
安定した株価: CNCE's share price has been volatile over the past 3 months.
時間の経過による変動: CNCE's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2006 | 64 | Roger Tung | www.concertpharma.com |
Concert Pharmaceuticals, Inc. 基礎のまとめ
| CNCE 基礎統計学 | |
|---|---|
| 時価総額 | US$520.71m |
| 収益（TTM） | -US$126.68m |
| 売上高(TTM) | US$32.04m |
16.3x
P/Sレシオ-4.1x
PER（株価収益率CNCE は割高か？
公正価値と評価分析を参照収益と収入
| CNCE 損益計算書（TTM） | |
|---|---|
| 収益 | US$32.04m |
| 売上原価 | US$102.70m |
| 売上総利益 | -US$70.66m |
| その他の費用 | US$56.02m |
| 収益 | -US$126.68m |
直近の収益報告
Sep 30, 2022
次回決算日
該当なし
| 一株当たり利益（EPS） | -2.04 |
| グロス・マージン | -220.53% |
| 純利益率 | -395.36% |
| 有利子負債／自己資本比率 | 0% |
CNCE の長期的なパフォーマンスは？
過去の実績と比較を見る